key: cord-0283868-zb0n2rq0
authors: Gayvert, Kaitlyn; Copin, Richard; McKay, Sheldon; Setliff, Ian; Lim, Wei Keat; Baum, Alina; Kyratsous, Christos A.; Atwal, Gurinder S.
title: Viral population genomics reveals host and infectivity impact on SARS-CoV-2 adaptive landscape
date: 2021-12-30
journal: bioRxiv
DOI: 10.1101/2021.12.30.474516
sha: 071dc9fbfa988b632c3d7ea0e92c802f9d42ada3
doc_id: 283868
cord_uid: zb0n2rq0

Public health surveillance, drug treatment development, and optimization of immunological interventions all depend on understanding pathogen adaptation, which differ for specific pathogens. SARS-CoV-2 is an exceptionally successful human pathogen, yet complete understanding of the forces driving its evolution is lacking. Here, we leveraged almost four million SARS-CoV-2 sequences originating mostly from non-vaccinated naïve patients to investigate the impact of functional constraints and natural immune pressures on the sequence diversity of the SARS-CoV-2 genome. Overall, we showed that the SARS-CoV-2 genome is under strong and intensifying levels of purifying selection with a minority of sites under diversifying pressure. With a particular focus on the spike protein, we showed that sites under selection were critical for protein stability and virus fitness related to increased infectivity and/or reduced neutralization by convalescent sera. We investigated the genetic diversity of SARS-CoV-2 B and T cell epitopes and determined that the currently known T cell epitope sequences were highly conserved. Outside of the spike protein, we observed that mutations under selection in variants of concern can be associated to beneficial outcomes for the virus. Altogether, the results yielded a comprehensive map of all sites under selection across the entirety of SARS-CoV-2 genome, highlighting targets for future studies to better understand the virus spread, evolution and success.

The coronavirus disease 2019 (COVID- 19) global pandemic has motivated a widespread effort to understand adaptation mechanisms of its etiologic agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As a result, scientists and medical professionals from around the world have sequenced the SARS-CoV-2 genome from patient isolates and disseminated their findings at unprecedented speed through curated data repositories such as the global initiative on sharing all influenza data (GISAID.

https://www.gisaid.org) 1,2 . This provided a unique dataset critical to determine transmission patterns and identify variants that may be associated with virulence and disease severity. This has become even more critical with the emergence of various variants under surveillance (VUS), which are associated with increased transmissibility and the potential to escape from natural immunity, therapeutic antibodies, and vaccine mediated immunity 3 .

To date, we still know little about the forces driving the conservation and diversity of SARS-COV-2 genome and the potential implication on treatment development and efficacy. While mutations emerge randomly in the genome, the accumulation or loss of variants can be beneficial to the virus within and across the host environment. This genetic adaptation can lead to both diversification or conservation of viral protein domains or amino acids and is key to the successful spread of SARS-CoV-2 in the human population. Selection driving amino acid conservation is called purifying or negative selection, and tends to conserve the integrity of a domain structure or function.

Conversely, selection leading to the accumulation of amino acid changes is called positive selection and may be associated with gain of function through molecular alterations.

During infection, pressure to escape recognition by antigen-targeting immune factors, such as antibodies and T lymphocytes, often leads to positive selection of viral antigens.

The consequences of antigenic variation can include persistent viral infection 4 , pandemics of diseases 5 , and reinfection after recovery 6, 7 . Antigenic variation can also impact therapeutics or vaccine efficacy, as it confounds development of treatments and vaccines that can protect against diverse viral strains 7-9 . Thus, characterizing which regions in the genome are conserved or diverse with an emphasis on antigenic targets has critical implications for drug development and resistance.

To date, both, B cell and T cell immune responses have been reported to play roles in controlling SARS-CoV-2 infections 10 . B cells produce both anti-SARS-CoV-2 neutralizing and non-neutralizing antibodies, which comprise the majority of the polyclonal responses.

Many of the most potently neutralizing anti-SARS-CoV-2 antibodies target the receptorbinding domain (RBD) of the viral spike protein, often competing with its binding to the ACE2 cell host receptor [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Antigen-specific T cells recognize short peptide epitopes generated by proteolysis of pathogen proteins, bound to HLA molecules on the surface of antigen-presenting cells. SARS-CoV-2 reactive memory CD4+ 22 To understand the forces shaping SARS-CoV-2 genome, and better inform treatment development, we analyzed an extensive dataset of 3,884,234 SARS-CoV-2 genome sequences available in GISAID. As the first vaccine against SARS-COV-2 was administered in December 2020 and distribution ramped up significantly only during spring 2021, the vast majority of these sequences pre-date the vaccine era. As such, they represent a great opportunity to identify and understand the impact of natural selection on sequence diversity of SARS-CoV-2 in naïve hosts. First, we established the evolutionary relationship of SARS-CoV-2 isolates and highlighted amino acid variants spreading in the community at high frequency. We then used evolutionary analysis to determine selection forces driving genetic diversity in SARS-CoV-2 at both protein and amino acid levels. Finally, we present a comprehensive genetic analysis of the currently known SARS-CoV-2 B and T cell epitopes to determine whether all SARS-CoV-2 antigens represent potential target of immune escape.

Since the first SARS-CoV-2 genome sequence was reported in early January 2020, there have been almost four million sequences deposited to GISAID as of late September 2021 (https://www.gisaid.org/) 1,2 . Each genome sequence is associated with comprehensive patient-related metadata that can be used to determine the time of infection and the geographical origin of the virus isolates ( Figure 1A) . We compared the identity of all coding sequences retrieved from 3,884,234 curated genomes. We found that 41% of all variants were identified in only one given isolate (singleton). Since singletons may be transient and destined to be removed by purifying selection, their biological significance is uncertain. However, there were 1,689 amino acid changes shared across at least 2,000 isolates (high frequency variants or HFV), with a disproportionate number coming from the ORF7a (n=61; out of 121 possible sites), ORF8 (n=51/121), and ORF3a (n=107/275).

Because the spike protein is the focus of most drug development efforts, characterization of its genetic diversity is critical for clinical surveillance and treatment outcome prediction.

HFV identified within the spike protein were found accumulating within the N-terminal domain (NTD) (31%; 90 / 291) ( Figure 1B) . The RBD had a lower number of HFV (9%; 20 / 223) when compared to the full spike protein (16%; 204 / 1,273) or to the SARS-CoV-2 genome (15%; 1,456 / 9,701) as a whole. Overall, the spike protein did not show any enrichment of sequence diversity compared to the SARS-CoV-2 entire genome sequence.

Detailed, rigorous analysis of a data set of four million genomes is challenging with current computing resources. To obtain computationally feasible data set, we developed a downsampling method to select a subset of 20,000 genomes (see Methods) 29, 30 . Genome-based phylogenetic analysis further resolved relationships among samples and the evolution of the virus in relation to geographic distribution. Many lineages contained SARS-CoV-2 isolates from several continents, indicating limited geographical clustering consistent with a global pandemic ( Figure 1C ). Comparison of the diversity of individual genomes by lineage allowed identification of mutations exhibiting several instances of convergent evolution ( Figure 1D ). These mutations included L452R and E484K, which were identified independently in genomes from at least 5 and 7 lineages, respectively.

This indicates that emergence of both mutations occurred as a result of similar selective forces in independent individuals rather than linear transmission. Because phylogenydefining mutations can be critical to understand virus biology, a further examination of positive and purifying selection and functional studies of how variants may impact SARS-CoV-2 biology was warranted.

Current Bayesian estimates of the SARS-CoV-2 genome mutation rate are approximately 7x10 -4 nucleotide substitutions per site per year 31, 32 , which is relatively low compared to other human coronaviruses and RNA viruses 32 . The low mutation rate may suggest that purifying selection dominates the SARS-CoV-2 genome. However, it does not rule out the possibility that some amino acid sites may be under positive selection. To characterize the selective forces driving SARS-CoV-2 gene sequence diversity, we applied a Bayesian codon model, FUBAR 30 , to identify sites evolving under natural selection. Codon substitution models estimate site-specific synonymous (dS, alpha) and nonsynonymous (dS, beta) substitution rates from a given sequence alignment and phylogeny, which in turn are used to identify sites that are evolving significantly faster (alpha<beta; positive selection) or slower (alpha>beta; purifying selection) than expected. Quickly spreading mutations under positive selection, especially those that arise independently across multiple lineages via convergent evolution, can be identified through these approaches Figure S1B ). This indicated that despite having a globally conserved genome, evolutionary analysis at the single amino acid level revealed sites with significant diversity. A comprehensive list of all sites under selection is provided as a supplemental table (Table S1 ).

To better understand how these levels of selection have changed over time, we repeated this analysis across seven additional temporal windows (sequences collected up until . We also detected sites that were under diversifying forces earlier in the pandemic but no longer appear to be under selection, including the N439K mutation in the RBD ( Figure S2 ).

To further characterize how sites under selection within the RBD may relate to the pressures of the host environment, we first determined the impact of variants under selection on infectivity. We assessed the functional constraints of ACE2 binding using previously published deep mutational screens that measured the impact of mutations on affinity for ACE2 binding and protein folding stability, as estimated by RBD expression 51 .

Substitutions at sites under purifying selection (83%) had the strongest negative impact on ACE2 binding affinity and protein stability ( Figure 3A , Figure S3A ). Conversely, sites under positive selection had less effect on binding or stability ( Figure 3A ). Since this screen was limited at estimating increased binding affinity due to global epistasis estimation, N501Y was the only HFV in the RBD that demonstrated a substantial increase ACE2 binding affinity in this analysis. However additional HFV have been reported to enhance binding affinity (N440K 52 , L452R 53,54 , S477N 44 , S477I 55 , T478K 46 , and S494P 56 ), and these changes have been linked to increased infectivity and transmissibility 44, 45, 53, 54 .

We next looked to assess how sites under selection impacted antibody neutralization. We compared how the site-level estimates of selection related to the four major classes of SARS-CoV-2 neutralizing antibodies ( Figure 3B ). Each class varies in its ability to block ACE2 (class 1, 2) and its binding configuration to the RBD (class 1, 4: "up"-only; class 2, 3: "up" and "down") 57 . While purifying selection applied to epitopes from all antibody classes, it had the strongest impact on epitopes from class 1 and class 4 antibodies ( Figure 3C ) and the lowest impact on epitopes from class 2 antibodies, which were reported to be associated with convalescent sera 50 (Table 1) .

Interestingly, we found that N501Y, E484K/Q and L452R/Q have all arisen independently across multiple lineages (N501Y in alpha, beta, gamma; E484K/Q in beta, gamma, iota, kappa; L452R/Q in delta, epsilon, kappa, lambda) 3 , indicating a common selective pressure acting on independent isolates. We also found that mutations at site 417 (K417N/beta; K417T/gamma) and 501 were physically linked in 95% of isolates (124,260/131,459). Because mutations at site 417 reduced antibody neutralization at a cost of ACE2 binding, and N501Y increased ACE2 affinity, the data suggested that some mutations can combine to alleviate the detrimental effect of individual variants.

Each of the currently characterized VUS contain at least one of the RBD HFVs that are associated with increased infectivity. Additionally, all except alpha also include a mutation that reduces antibody neutralization. The impact of the K417N/T and E484K on convalescent sera may have enabled the beta and gamma variants to spread in South Africa 68 and Brazil 69 despite high levels of seroprevalence in the late 2020 to early 2021 periods. To further investigate this, we annotated each isolate collected in 2020 with the incident rate (cases per 100,000) estimated from the geographic region and month from which the sample was collected, which we found to be a strong correlate with seroprevalence in the pre-vaccine era ( Figure S4 ). We observed that the variants that reduced antibody neutralization were found in areas with significantly higher seroprevalence ( Figure 3E ). While most of the vaccines continue to demonstrate strong efficacy against the currently circulating variants, the beta and gamma variants have led to the discontinuation of both therapeutic antibodies (eg. bamlanivimab, etesevimab) 70 and specific vaccines (e.g. ChAdOx1) 71 due to loss of efficacy. Altogether, this suggests that the mutations associated with reduced neutralization have serious implications for public health.

In order to determine if SARS-CoV-2 mutations occur in regions targeted by the human 

A significant finding of the present study is the strong evidence that SARS-CoV-2 antigen and epitope conservation is the rule, not the exception, in this highly successful human pathogen. The SARS-CoV-2 RBD is both the region mediating viral entry into the cell and the main target of potent neutralizing anti-spike antibodies in COVID-19 patient sera or plasma samples 72, 73 . Therefore, most of the selective pressure imposed by the immune system of the host should target this domain. Close examination of RBD conservation indicated that while the RBD as a whole was under extensive purifying selection, consistent with the functional constraints imposed on this region, there were individual sites under strong levels of diversification. We found that these sites were associated with increased ACE2 binding and infectivity, as well as reduced neutralization by convalescent and therapeutic antibodies.

The HFV at position 417 of the RBD (K417N/T) presented a particularly interesting case.

While these mutations reduce neutralization of therapeutic and convalescent antibodies 47, 58 , this occurs at the fitness cost of reduced ACE2 binding affinity. We found that mutations at this site have not been successful in spreading without the addition of the compensatory mutation N501Y. Experimental studies have confirmed that while K417N alone results in a significant drop in ACE2 binding affinity, its combination with N501Y resulted in 3-fold stronger binding than wild-type (although still 2-fold less compared to N501Y alone) 74 . More recently, K417N has also been found in two sublineages of delta (AY.1, AY.2). While these variants do not include N501Y, they do include a different compensatory mutation that increases ACE2 binding affinity, L452R.

Neutralizing monoclonal antibodies have also been isolated that target non-RBD epitopes genes. This can be explained by the roles these genes have been described to play in interacting with the immune system to block the innate immune response.

Additionally, the N R203M mutation associated with the delta variant was described to significantly increase mRNA production and delivery in to host cells and thus explain the In conclusion, our findings indicated that SARS-CoV-2 genetic selection is driven by a deterministic process imposed by natural within-host purifying selection, leading to a dominant lineage mode of evolution. However, our results also showed that this pathogen is capable of genetic plasticity dictated by environmental changes. The necessity to adapt leads to selection and the contribution of dominant genotypes determined by the host. 

The approximately 4.7 million complete genome sequences deposited in GISAID 1,2 as of September 26, 2021 were downloaded along with their variant calls and accompanying metadata. GISAID genomes were filtered to remove poor quality sequences using the following criteria: complete metadata, less than 2% ambiguous DNA sequence (N) or protein (X) with no runs of 4 or more Ns in the genome or Xs in the proteins, all genes 

The downsampled subset of 20,000 genomes and the corresponding portion of the Audacity tree were used to perform a further, phylogeny-guided subsample of 1000 genomes with Treemmer 81 to reduce the sample size while preserving sequence diversity. Where available, at least 10 representatives of the variant lineages were protected from down-sampling to ensure they were represented in the final tree. A wholegenome maximum likelihood tree of the 1000 sequences was constructed using iqtree2 82 with the GTR+F+R3 model. The phylogenetic tree was outgroup rooted using a related bat betacoronvirus genome (RATG13; GISAID accession EPI_ISL_402131) to infer the evolutionary branching order of SARS-CoV-2 lineages. Phylogenetic trees were annotated with geographic and variant metadata using the ETE3 Python toolkit 83 . Images of annotated phylogenetic trees were rendered using the Python API to iTOL, the interactive Tree of Life 84 .

The selection test was performed using Fast Unconstrained Bayesian AppRoximation (FUBAR) method 30 from the hypothesis testing using phylogenies (HyPhy) Suite (https://stevenweaver.github.io/hyphy-site). The analysis was conducted for each single gene. The prepared alignment and corresponding phylogenies described above were sent to FUBAR to infer nonsynonymous (dN) and synonymous substitution (dS) rates at a per-site basis and test whether dN was significantly different from dS. Sites with probability values > 0.9 were considered to be under non-neutral selection.

To assess whether the genome subsets were representative of the larger data set and that any results will be robust and reproducible, his analysis was repeated across five different replicates of the above-described downsampling procedure. The consistency of the results was assessed using Pearson correlation of the log(1 -probabilities) of positive selection across the full SARS-CoV-2 genome. There was a high degree of concordance among replicates ( Figure S7 ). This suggested that these downsampled subsets were sufficiently representative of the larger dataset and could be used to further investigate the evolution of the SARS-CoV-2 genome.

Using the output of variant calling scripts, we identified how many viruses were sequenced that contained a mutation from the wild type sequence at each position. These frequencies were used to annotate the B-factor of PDB file 6VSB 85 with PDB ID 6M0J 86 with PDB ID 6M0J 86 superimposed on one protomer of 6VSB in order to provide resolution on residues in VUS which lacked resolution in 6VSB; The resulting chimeric structure was used to color each atom using PyMOL's spectrum command.

Data from deep mutational scans was downloaded from https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS (RBD binding, expression constraints) and https://github.com/jbloomlab/SARS2_RBD_Ab_escape_maps (escape maps). The escape value was taken to be the average of "normalized_site_total_escape" for site-level and average of "mut_escape" for mutationlevel across all convalescent plasma samples.

CDC seroprevalence estimates was downloaded from https://covid.cdc.gov/covid-datatracker/#serology-surveillance. The John Hopkins daily incident rate estimates were downloaded from https://github.com/CSSEGISandData/COVID-19. For each US state, the relationship between seroprevalence estimates and incident rates was evaluated using Pearson's correlation coefficient. Since these were highly correlated (R=0.8), the incident rate was used as a proxy for seroprevalence. For each sample in GISAID, the incident rate at the month (Collection Date) and highest-resolution place (county when available, otherwise state/country) was annotated. The incident rates were used to compare trends where different sets of mutations are spreading. This analysis was restricted to the pre-vaccination era of sequences, as defined by the samples collected between June 2020 (when incident rates became reliable) and December 31, 2020 (when vaccinations began to ramp up in the United States).

The list of 142 previously published memory CD4 + T cell epitope sequences and genome coordinates was downloaded from Supplementary Table 1 (E) Boxplot of the incident rates (cases per 100,000) for each sample in the prevaccination era (collected in 2020) with one of the RBD HFV in Table 1 , grouped by whether that sample contains a mutation that reduces neutralization, increased ACE2 binding without any impact on neutralization, or no effect on neutralization and binding. Figure S4 A B Figure S7 

Data, disease and diplomacy: GISAID's innovative contribution to global health

Global initiative on sharing all influenza data -from vision to reality

SARS-CoV-2 Variant Classifications and Definitions

Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination

Mechanisms of replacement of circulating viruses by seasonal and pandemic influenza A viruses

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets

Immune control of HIV: the obstacles of HLA and viral diversity

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Potently neutralizing and protective human antibodies against SARS-CoV-2

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8(+) T cell activation in COVID-19 patients

Patterns of intra-and interhost nonsynonymous variation reveal strong purifying selection in dengue virus

Fluid Spatial Dynamics of West Nile Virus in the United States: Rapid Spread in a Permissive Host Environment

Comparative analysis of protein evolution in the genome of preepidemic and epidemic Zika virus

Impact of spatial dispersion, evolution, and selection on Ebola Zaire Virus epidemic waves

Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

FUBAR: a fast, unconstrained bayesian approximation for inferring selection

Phylogenetic reconstruction of the initial stages of the spread of the SARS-CoV-2 virus in the Eurasian and American continents by analyzing genomic data

Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States

The phylogenomics of evolving virus virulence

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans

SARS-CoV-2 genomic surveillance identifies naturally occurring truncations of ORF7a that limit immune suppression

Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities

Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein

Potent SARS-CoV-2 neutralizing antibodies directed against spike Nterminal domain target a single supersite

SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

The impact of Spike mutations on SARS-CoV-2 neutralization. bioRxiv

Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677

Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Emerging vaccine-breakthrough SARS-CoV-2 variants

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Comprehensive mapping of mutations in the SARS-CoV-2 receptorbinding domain that affect recognition by polyclonal human plasma antibodies

SARS-CoV-2 variants, spike mutations and immune escape

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Prediction of the Effects of Variants and Differential Expression of Key Host Genes ACE2, TMPRSS2, and FURIN in SARS-CoV-2 Pathogenesis: An In Silico Approach

Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Neutralizing Antibody Therapeutics for COVID-19

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant

Detection of a SARS-CoV-2 variant of concern in South Africa

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

HHS. Pause in the Distribution of bamlanivimab/etesevimab

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles

Origin and evolution of pathogenic coronaviruses

VIRULIGN: fast codon-correct alignment and annotation of viral genomes

A phylogeny-based metric for estimating changes in transmissibility from recurrent mutations in SARS-CoV-2. bioRxiv

Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity

IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era

ETE 3: Reconstruction, Analysis, and Visualization of Phylogenomic Data

Interactive Tree Of Life (iTOL) v4: recent updates and new developments

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor